ClinicalTrials.gg
RecruitingNCT07413562MARS-TBIUpdated Feb 17, 2026

Feasibility, Safety, and Preliminary Efficacy of Median Nerve Stimulation for Cognitive Dysfunction in Patients With Acute Traumatic Brain Injury

An interventional study of Median nerve stimulation and Sham in Traumatic Brain Injury and Cognitive Dysfunction, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2025, registered Feb 2026).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.

Planned enrollment
22nd of 26
30 · median 83
Started
2025
with 6 others
No phase
18 of 60
8 open now
Primary completion
2026-09
later than 14 of 29 live
Registered
57th of 60
by date
Lead sponsor
6 of 60
Beijing Tiantan Hospital

Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 14 of the 29 other live ones, and was the 57th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Brain Injuries, Traumatic with a site in China, or all of them as a file.
02

Study summary

Currently, the treatment of cognitive dysfunction after acute TBI remains a challenge, and novel therapeutic methods are urgently needed. Median nerve stimulation (MNS) is a non-invasive neuromodulation technique and recently has shown positive effects in awaking coma of acute brain injury. It has been shown to improve cognition in healthy volunteers and may be a potential therapeutic approach for cognitive dysfunction in patients with acute TBI. Therefore, the main purpose of the study is to evaluate the feasibility, safety, and preliminary efficacy of MNS for cognitive dysfunction in patients with acute TBI.

Read the detailed description

Traumatic brain injury (TBI), a major cause of death and disability, is a significant public health problem in the worldwide. It can cause cognitive dysfunctions including executive function, memory, attention, language and visuospatial function, which seriously affects the patient's quality of life and places a heavy burden on the country and family. Currently, the main therapeutic methods for cognitive impairment include cognitive training, drug therapy, hyperbaric oxygen therapy, and aerobic exercise therapy. They all have been shown to have potentially positive effects on cognitive impairment. However, the improvement in overall cognitive function is inconsistent. Moreover, all the interventions are usually performed during chronic stage of TBI, leading to often delayed and suboptimal therapeutic outcomes. Thus, treatment options for cognitive impairment during the acute stage of TBI remain limited.

Recently, noninvasive neuromodulation techniques, including repetitive transcranial magnetic stimulation, transcranial direct current stimulation, transcutaneous auricular vagus nerve stimulation, and median nerve stimulation, were recognized to have promising potentials in improving cognitive function in patients with cognitive impairment caused by stroke, intracerebral hemorrhage, and TBI. Within them, MNS is a simple, inexpensive, and noninvasive neuromodulation technique that has been found to improve recovery from TBI, hasten awakening from coma in our previous study. Furthermore, clinical studies have shown that it can effectively improve cognitive function in healthy individuals and enhance cognitive recovery following stroke. However, whether MNS has the same beneficial effects in those with cognitive dysfunction after TBI is unclear. The investigators designed the present study to assess the feasibility and safety of MNS and the preliminary effects on cognitive dysfunction in patients with acute TBI. The present study details a pilot trial that will be conducted before a large-scale randomized controlled trial.

03

Conditions studied

  • Traumatic Brain Injury
  • Cognitive Dysfunction

Keywords

  • Traumatic Brain Injury
  • Cognitive dysfunction
  • Median nerve stimulation
  • Neuromodulation
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-64 years.
  2. Admitted within 3 days post-injury with a Glasgow Coma Scale (GCS) score of 9-12 at admission, accompanied by imaging abnormalities.
  3. Presence of cognitive dysfunction assessed within 1-week after injury, with a (MMSE) score ≤26.
  4. Pre-injury Clinical Dementia Rating (CDR) score = 0 as reported by family members.
  5. With a pre-injury education of ≥6 years, able to comprehend instructions and cooperate in completing scale assessments, magnetic resonance imaging (MRI), and magnetoencephalography (MEG) examinations.

Exclusion criteria

Exclusion Criteria:

  1. Requirement for emergent neurosurgical intervention during treatment including surgery, intracranial pressure monitoring device placement, or drainage catheter insertion.
  2. Unstable vital signs or hemodynamics, or presence of unstable cardiac, pulmonary, hepatic, renal, or hematopoietic system disorders.
  3. Pre-existing central nervous system conditions causing cognitive decline: traumatic brain injury, intracranial infection, brain tumor, epilepsy, stroke, neurodegenerative diseases, carbon monoxide poisoning, and alcohol abuse.
  4. Inability to complete assessments or examinations due to severe visual or auditory impairment, severe psychiatric or behavioral disorders, MRI , and MEG intolerance.
  5. Short due to critical illnesses.
  6. Right forearm with extensive skin lesions or scars, right median nerve injury, brachial plexus injury, cervical spinal cord injury, or intolerance to MNS.
  7. Pregnant or lactating women.
  8. Participation in other ongoing clinical trials.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Median nerve stimulation group

    Participants will receive right median nerve stimulation therapy (right median nerve electrical stimulator, XCH-B1, Jiangxi Nuocheng Electrical Equipment Co., Ltd.). Both frequency of 40 Hz and pulse width of 300 µs are fixed and applied within a 20-s on/40-s off protocol. Stimulation will be administered for 8 hours per day over a 2-week period.

    Device: Median nerve stimulation

  • Sham comparator
    Sham group

    The participants in the sham stimulation group will receive no electrical stimulation (0 mA) via an activated stimulator, with all other device settings and procedures identical to those used in the active stimulation group.

    Drug: Sham

Interventions

  • DeviceMedian nerve stimulation

    Participants will receive right median nerve stimulation therapy (right median nerve electrical stimulator, XCH-B1, Jiangxi Nuocheng Electrical Equipment Co., Ltd.). Both frequency of 40 Hz and pulse width of 300 µs are fixed and applied within a 20-s on/40-s off protocol. Stimulation will be administered for 8 hours per day over a 2-week period.

  • DrugSham

    The participants in the sham stimulation group will receive no electrical stimulation (0 mA) via an activated stimulator, with all other device settings and procedures identical to those used in the active stimulation group.

06

What researchers measure

Primary outcomes

  1. Change in global cognitive function assessed by the Mini-Mental State Examination(MMSE)

    The MMSE will be used to evaluate global cognitive function. Assessments will be conducted by two trained occupational researchers who are blinded to group allocation and not involved in the intervention.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

Secondary outcomes

  1. Global cognitive function (MoCA)

    Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a 30-point screening tool evaluating multiple cognitive domains including attention, memory, language, executive function, and visuospatial ability. Higher scores indicate better cognitive performance, and a score below 26 suggests cognitive impairment.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  2. Verbal fluency

    Verbal fluency will be assessed using the Verbal Fluency Test, in which participants are asked to generate as many words as possible within 1 minute. The test evaluates language production and executive control, with higher word counts indicating better performance.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  3. Language function

    Language ability will be assessed using the Boston Naming Test, which requires participants to name a series of visually presented objects. Higher scores reflect better confrontation naming ability and language function.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  4. Visuospatial function

    Visuospatial ability will be assessed using the Rey-Osterrieth Complex Figure Test (RCFT), which evaluates visuospatial construction and visual memory through figure copying and recall tasks. Higher scores indicate better visuospatial performance.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  5. Verbal learning and memory

    Verbal learning and memory will be assessed using the Rey Auditory Verbal Learning Test (RAVLT), a verbal learning task involving a 15-item word list learned over five trials. The delayed recall score represents the number of correctly recalled words (range: 0-15) after a 30-minute delay, with higher scores indicating better memory performance.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  6. Executive function

    Executive function will be assessed using the Stroop Test and Trail Making Test A/B. The Stroop Test evaluates inhibitory control and cognitive flexibility, while the Trail Making Test assesses processing speed (Part A) and set-shifting ability (Part B). Better executive function is reflected by higher accuracy and shorter completion time.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  7. Attention and working memory

    Attention and working memory will be assessed using the Digit Symbol Test and Digit Span Test. The Digit Symbol Test evaluates attention and processing speed, whereas the Digit Span Test assesses working memory capacity through forward and backward recall tasks. Higher scores indicate better cognitive performance.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  8. Neuropsychiatric symptoms

    Neuropsychiatric symptoms will be assessed using the Neuropsychiatric Inventory (NPI), which evaluates 12 neuropsychiatric symptom domains based on caregiver interviews, including both the caregiver's observations of patient behaviors and the associated caregiver distress. The total patient symptom score ranges from 0 to 144, and the caregiver distress score ranges from 0 to 60, with higher scores indicating greater symptom frequency, severity, and caregiver burden; a score of 0 represents the absence of symptoms or distress.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  9. Sleep quality

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), which consists of 19 self-rated items measuring seven domains of sleep: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbances, (6) use of sleep medication, and (7) daytime dysfunction. The 19 items are aggregated into seven component scores, each ranging from 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. The component scores are summed to generate a global PSQI score ranging from 0 to 21, with higher scores indicating poorer overall sleep quality.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  10. Anxiety symptoms

    Anxiety symptoms will be assessed using the Hamilton Anxiety Scale (HAMA), a clinician-rated scale where higher scores indicate more severe anxiety symptoms.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  11. Depressive symptoms

    Depressive symptoms will be assessed using the Hamilton Depression Scale (HAMD), where higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  12. Apathy

    Apathy will be assessed using the Modified Apathy Evaluation Scale (MAES), a questionnaire evaluating motivational and emotional engagement. The total score ranges from 0 to 42, with scores greater than 14 indicating apathy; higher scores represent more severe apathetic symptoms.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  13. Agitation

    Agitation will be assessed using the Cohen-Mansfield Agitation Inventory (CMAI), a 29-item observational scale designed to assess agitation behaviors related to dementia and delirium. The CMAI measures the frequency of agitated behaviors across multiple categories, with total scores ranging from 29 to 116; higher scores indicate more severe agitation.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  14. Level of consciousness

    Neurological status will be assessed using the Glasgow Coma Scale (GCS), a 15-point scale ranging from 3 to 15, where higher scores indicate better level of consciousness.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  15. Functional neurological outcome

    Functional neurological outcome will be assessed using the Modified Rankin Scale (mRS), which ranges from 0 to 6, where higher scores indicate worse functional outcome. A score of 0 indicates normal daily functioning, and a score of 6 indicates death.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  16. Activities of daily living

    Activities of daily living will be assessed using the Modified Barthel Index (MBI), a 100-point scale evaluating functional independence in basic daily activities. Higher scores indicate greater independence. Scores \<20 indicate very severe functional dependence with complete reliance on others; scores of 20-40 indicate severe dependence requiring substantial assistance; scores of 41-60 indicate moderate dependence; and scores \>60 indicate basic independence in daily living.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  17. Health-related quality of life

    Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36), which evaluates physical and mental health domains, where higher scores indicate better quality of life.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  18. Functional activities

    Functional activities will be assessed using the Functional Activities Questionnaire (FAQ; range 0-30), with higher scores indicating worse functional performance. Scores ≤5 are considered normal, whereas scores ≥5 suggest impaired independence in home and community functioning.

    Time frame: Baseline (Day 7 after injury), 1 month after injury, and 3 months after injury.

  19. Neuroimaging outcomes

    Functional connectivity of brain networks will be assessed using magnetoencephalography (MEG), with quantification of connectivity within the default mode network and executive control network.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

  20. Serum tau level

    Serum tau concentration will be measured as a biomarker of neuronal injury, where higher levels may indicate greater neuronal damage.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

  21. Serum amyloid-β (Aβ) level

    Serum amyloid-β (Aβ) concentration will be measured as a biomarker related to cognitive impairment, where higher levels may indicate increased pathological burden.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

  22. Serum glial fibrillary acidic protein (GFAP) level

    Serum GFAP concentration will be measured as a biomarker of astroglial injury, where higher levels may indicate greater glial damage.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

  23. Serum S100β level

    Serum S100β concentration will be measured as a biomarker of blood-brain barrier disruption and glial injury, where higher levels may indicate worse neurological injury.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

  24. Serum α-synuclein level

    Serum α-synuclein concentration will be measured as a biomarker related to neuronal degeneration, where higher levels may indicate greater neuronal pathology.

    Time frame: Baseline (Day 7 after injury) and 1 month after injury.

Other outcomes

  1. Feasibility outcomes

    Feasibility will be evaluated by enrollment rate, recruitment rate, adherence rate (proportion of completed scheduled stimulation hours), and retention rate (completion of all outcome assessments).

    Time frame: From baseline (Day 7 after injury) to 3 months after injury.

  2. Safety outcomes

    Adverse events related to the intervention (e.g., skin pain, uncomfortable cutaneous sensations, dizziness, abnormal blood pressure, or heart rhythm disturbances) will be recorded. Side effects will be monitored using a 10-item Likert-scale questionnaire (score range: 1 = absent to 5 = severe).

    Time frame: From baseline (Day 7 after injury) to 3 months after injury.

07

Study locations

1 of 1 sites recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100070, China
    Recruiting
    • Guoyi Gao, MD · Contactgao3@sina.com · 13801874393
    • Liang Wu, MD · Contactwuliang@bjtth.org · 18301674233
    • Guoyi Gao, MD · Principal investigator
    • Liang Wu, MD · Sub investigator
    • Weiming Liu, MD · Sub investigator
    • Yu Deng, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 19 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 17, 2026
StartActual
Feb 1, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413562
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 1, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Liang Wu, MD
Contact
wuliang@bjtth.org
18301674233 ext. +86
Yu Deng, MD
Contact
drdy1998@126.com
15611308032 ext. +86
Guoyi Gao, MD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion